Literature DB >> 20042725

Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo-induced central memory CD8 T cells.

Eran Ophir1, Yaki Eidelstein, Ran Afik, Esther Bachar-Lustig, Yair Reisner.   

Abstract

Enabling engraftment of allogeneic T cell-depleted bone marrow (TDBM) under reduced-intensity conditioning represents a major challenge in bone marrow transplantation (BMT). Anti-third-party cytotoxic T lymphocytes (CTLs) were previously shown to be endowed with marked ability to delete host antidonor T cells in vitro, but were found to be less effective in vivo. This could result from diminished lymph node (LN) homing caused by the prolonged activation, which induces a CD44(+)CD62L(-) effector phenotype, and thereby prevents effective colocalization with, and neutralization of, alloreactive host T cells (HTCs). In the present study, LN homing, determined by imaging, was enhanced upon culture conditions that favor the acquisition of CD44(+)CD62L(+) central memory cell (Tcm) phenotype by anti-third-party CD8(+) cells. These Tcm-like cells displayed strong proliferation and prolonged persistence in BM transplant recipients. Importantly, adoptively transferred HTCs bearing a transgenic T-cell receptor (TCR) with antidonor specificity were efficiently deleted only by donor-type Tcms. All these attributes were found to be associated with improved efficacy in overcoming T cell-mediated rejection of TDBM, thereby enabling high survival rate and long-term donor chimerism, without causing graft-versus-host disease. In conclusion, anti-third-party Tcms, which home to recipient LNs and effectively delete antidonor T cells, could provide an effective and novel tool for overcoming rejection of BM allografts.

Entities:  

Mesh:

Year:  2009        PMID: 20042725      PMCID: PMC2837324          DOI: 10.1182/blood-2009-10-248716

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Preferential localization of effector memory cells in nonlymphoid tissue.

Authors:  D Masopust; V Vezys; A L Marzo; L Lefrançois
Journal:  Science       Date:  2001-03-01       Impact factor: 47.728

2.  Visualizing the generation of memory CD4 T cells in the whole body.

Authors:  R L Reinhardt; A Khoruts; R Merica; T Zell; M K Jenkins
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

3.  Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes.

Authors:  N Manjunath; P Shankar; J Wan; W Weninger; M A Crowley; K Hieshima; T A Springer; X Fan; H Shen; J Lieberman; U H von Andrian
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

4.  Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34(+) cells.

Authors:  Hilit Gur; Rita Krauthgamer; Alain Berrebi; Tirza Klein; Arnon Nagler; Antonio Tabilio; Massimo F Martelli; Yair Reisner
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

5.  Total body irradiation causes profound changes in endothelial traffic molecules for hematopoietic progenitor cell recruitment to bone marrow.

Authors:  Irina B Mazo; Elizabeth J Quackenbush; John B Lowe; Ulrich H von Andrian
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

Review 6.  Migration and differentiation of CD8+ T cells.

Authors:  Wolfgang Weninger; N Manjunath; Ulrich H von Andrian
Journal:  Immunol Rev       Date:  2002-08       Impact factor: 12.988

Review 7.  Mixed chimerism and transplantation tolerance.

Authors:  T Wekerle; M Sykes
Journal:  Annu Rev Med       Date:  2001       Impact factor: 13.739

Review 8.  Transplants across human leukocyte antigen barriers.

Authors:  Massimo F Martelli; Franco Aversa; Ester Bachar-Lustig; Andrea Velardi; Shlomit Reich-Zelicher; Antonio Tabilio; Hilit Gur; Yair Reisner
Journal:  Semin Hematol       Date:  2002-01       Impact factor: 3.851

9.  Migratory properties of naive, effector, and memory CD8(+) T cells.

Authors:  W Weninger; M A Crowley; N Manjunath; U H von Andrian
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

10.  Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells.

Authors:  B K Cho; V P Rao; Q Ge; H N Eisen; J Chen
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

View more
  10 in total

1.  The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.

Authors:  N Or-Geva; Y Reisner
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 2.  Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers.

Authors:  Y-J Chang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

3.  Towards 'off-the-shelf' genetically modified T cells: prolonging functional engraftment in mice by CD8 veto T cells.

Authors:  N Or-Geva; R Gidron-Budovsky; L Radomir; Y Edelstein; A K Singh; R Sidlik-Muskatel; E Ophir; E Bachar-Lustig; Y Reisner
Journal:  Leukemia       Date:  2017-11-20       Impact factor: 11.528

4.  Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells.

Authors:  Eran Ophir; Noga Or-Geva; Irina Gurevich; Orna Tal; Yaki Eidelstein; Elias Shezen; Raanan Margalit; Assaf Lask; Guy Shakhar; David Hagin; Esther Bachar-Lustig; Shlomit Reich-Zeliger; Andreas Beilhack; Robert Negrin; Yair Reisner
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

5.  A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells.

Authors:  Assaf Lask; Eran Ophir; Noga Or-Geva; Adva Cohen-Fredarow; Ran Afik; Yaki Eidelstein; Shlomit Reich-Zeliger; Bar Nathansohn; Matthias Edinger; Robert S Negrin; David Hagin; Yair Reisner
Journal:  Blood       Date:  2013-02-27       Impact factor: 22.113

6.  Xenotransplantation: Where Are We with Potential Kidney Recipients? Recent Progress and Potential Future Clinical Trials.

Authors:  Kazuhiko Yamada; Jigesh A Shah; Tatsu Tanabe; Miguel A Lanaspa; Richard J Johnson
Journal:  Curr Transplant Rep       Date:  2017-05-08

7.  Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cells.

Authors:  Aloukick Kumar Singh; Elias Schetzen; Sandeep Kumar Yadav; Esther Bachar Lustig; Wei-Hsin Liu; Raj Kumar Yadav; Robert Peter Gale; Kathryn McGinnis; Yair Reisner
Journal:  Bone Marrow Transplant       Date:  2021-03-03       Impact factor: 5.174

8.  5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity.

Authors:  Thomas Stübig; Anita Badbaran; Tim Luetkens; York Hildebrandt; Djordje Atanackovic; Thomas M C Binder; Boris Fehse; Nicolaus Kröger
Journal:  Mediators Inflamm       Date:  2014-03-13       Impact factor: 4.711

9.  A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells.

Authors:  David H Quach; Luis Becerra-Dominguez; Rayne H Rouce; Cliona M Rooney
Journal:  J Transl Med       Date:  2019-07-24       Impact factor: 5.531

10.  The use of donor-derived veto cells in hematopoietic stem cell transplantation.

Authors:  Eran Ophir; Yair Reisner
Journal:  Front Immunol       Date:  2012-05-02       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.